Anti-Hypertensive Market Value is expected to increase to $44.5 billion by 2017, Reveals New Report

“Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries" analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the major developed markets. Increased uptake of combination therapies for treating hypertension will sustain the anti-hypertensive market, despite a series of upcoming patent expiries. In addition, an increase in the prescription of renin inhibitors (Tekturna/Rasilez) over the forecast period will also support market growth.

Senior Analyst says: "The substantial number of active drug candidates, spread across the various stages of clinical development, demonstrates a strong overall pipeline. However, the novel approach is currently limited to a few targets, most notably nondihydropyridine dual L/T-type calcium channel blockers (ACT-280778), Rho-associated kinase inhibitors (AN-3485) and vitamin D receptor agonists (CARD-024)."

Reasons to Buy

• This analysis combines complex data methodologies and detailed scientific writing to help clients to identify and understand real opportunities
• The report will support business development strategies of companies seeking to develop anti-hypertensive therapies with profiles that offer benefits over existing treatments
• Clinical trial benchmarks at the indication, therapy area and industry levels to build investment cases and risk profiles
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Market and product-specific forecasts to 2020, taking into consideration a wide range of factors, acknowledging the uncertainty in the market and providing insights into the scale of variation of diverse factors such as epidemiology trends, current and future treatment patterns, unmet needs, penetration rate, drug pricing and depreciation rates

Reasons for failure is one of several important clinical trial metrics developed by Publisher to help inform a thorough understanding of the entire developmental pipeline

The various issues responsible for the high failure rate are patient accrual issues, efficacy issues, safety concerns, trial difficulties, and business and finance-related issues. Most of the reasons for the termination/suspension of clinical trials on anti-hypertensive drugs are unknown or undisclosed

Associated metrics include clinical trial size by phase and molecule type, recruitment, trial duration and failure rate

Browse this report: http://mrr.cm/ZAJ